Axonyx To Host Webcast to Discuss 2003 Phenserine Clinical Program.Business Editors NEW YORK--(BUSINESS WIRE)--Jan. 22, 2003 AXONYX Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AXYX) announced today that it will host a webcast on January 29, 2003 at 10:00AM EST EST electroshock therapy. EST abbr. electroshock therapy . The participants from Axonyx will include Marvin S. Hausman, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , and Gosse B. Bruinsma, M.D., COO. In addition, Steven H. Ferris, Ph.D. a member of the Axonyx Board of Directors and Friedman Professor and Director of the Alzheimer's Disease Center at New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the School of Medicine, and Jack T. Rogers, Ph.D., Assistant Professor, Department of Psychiatry and Neuroscience, Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. will be co-hosts. The webcast will provide further details on the planned 2003 clinical program that is expected to generate additional data on the safety and efficacy of Phenserine in Alzheimer's patients, as well as provide evidence of Phenserine's ability to inhibit the underlying pathological amyloid process in these patients. The conference call will be open to all interested parties through a real-time audio web broadcast at the Axonyx corporate web site, www.axonyx.com. Those wishing to participate by phone can do so by dialing 1-877-329-7569 ten minutes before the conference begins and ask to be connected to the Axonyx conference call. International callers please dial 1-201-210-3425. Access to the rebroadcast will be available immediately following the call through February 29, 2003. The U.S. call in number is 1-877-347-9473. International callers please dial 1-201-210-3410. The re-broadcast pass code I.D. number is 217339. About Axonyx Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's disease, human memory disorders and prion-based illnesses such as Mad Cow Disease mad cow disease: see prion. mad cow disease or bovine spongiform encephalopathy (BSE) Fatal neurodegenerative disease of cattle. Symptoms include behavioral changes (e.g. . |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion